Nesiritide
recombinant human B-type natriuretic peptide, rhBNP, BNP-32, hBNP
Nesiritide is recombinant human B-type natriuretic peptide, identical to the 32-amino-acid hormone the failing heart releases in response to wall stretch. Given intravenously it dilates veins and arteries and lowers cardiac filling pressures. It was approved in the US in 2001 on the strength of those haemodynamic effects, but the definitive 7,141-patient trial, ASCEND-HF, found no clinical benefit, which is why it is now a case study in the difference between a good surrogate and a good outcome.
Mechanism
Nesiritide is produced in Escherichia coli and is structurally identical to endogenous human BNP-32, including the seventeen-residue ring closed by a disulfide bond between cysteines 10 and 26. BNP is secreted by ventricular myocytes in response to wall stress; nesiritide simply supplies it exogenously at pharmacological concentrations.
Its receptor is natriuretic peptide receptor A (NPR-A, also called guanylyl cyclase A). Binding activates the receptor's intrinsic guanylyl cyclase domain, raising intracellular cyclic GMP and activating protein kinase G. In vascular smooth muscle this reduces intracellular calcium and produces balanced venodilation and arterial dilation, cutting preload and afterload; in the kidney it increases glomerular filtration pressure and inhibits sodium reabsorption in the collecting duct; and systemically it suppresses renin, aldosterone, endothelin and sympathetic outflow. The net physiological effect is exactly what a decompensated heart appears to need: lower filling pressures, natriuresis, and antagonism of the neurohormonal cascade that drives progression.
Elimination occurs by three routes (binding to the clearance receptor NPR-C followed by endocytosis, enzymatic degradation by neprilysin, and renal filtration), giving a very short terminal half-life and requiring continuous infusion. The same neprilysin pathway is the target of the modern combination sacubitril/valsartan, which raises endogenous natriuretic peptides rather than infusing them, and has produced the mortality benefit nesiritide never did.
What the research shows
The early evidence was haemodynamic and looked persuasive. Colucci and colleagues (2000) reported across two parallel trials totalling 432 patients that nesiritide reduced pulmonary capillary wedge pressure by 6.0 to 9.6 mmHg depending on dose, against a 2.0 mmHg rise with placebo (p<0.001), with improvement in global clinical status in 60-67% of treated patients versus 14% on placebo. The VMAC trial (2002, 489 patients) compared nesiritide with intravenous nitroglycerin and placebo and formed the basis of FDA approval: nesiritide reduced wedge pressure more than either comparator at three hours and improved self-reported dyspnoea versus placebo at three hours, though by 24 hours the differences in dyspnoea were modest.
Safety concerns then accumulated. A meta-analysis of five randomised trials (1,269 patients) by Sackner-Bernstein and colleagues found a relative risk of worsening renal function of 1.52 (95% CI 1.16-2.00, p=0.003) with nesiritide at approved doses compared with non-inotrope controls, and 1.54 (95% CI 1.19-1.98) versus any control, without a difference in dialysis requirement. A companion analysis raised a signal for increased short-term mortality. These publications, from small trials not designed to address either question, triggered the trial that settled the matter.
ASCEND-HF randomised 7,141 patients hospitalised with acute heart failure to nesiritide or placebo on top of standard care. Dyspnoea improvement favoured nesiritide at 6 hours (44.5% versus 42.1%, p=0.03) and 24 hours (68.2% versus 66.1%, p=0.007) but did not cross the prespecified significance threshold. The composite of 30-day rehospitalisation for heart failure or death was 9.4% with nesiritide versus 10.1% with placebo (no significant difference), and 30-day mortality was 3.6% versus 4.0%. Reassuringly, the renal safety signal was not confirmed: rates of worsening renal function were no higher. Hypotension was significantly more common. The investigators concluded that nesiritide could not be recommended for routine use in the broad population of patients with acute heart failure. The subsequent ROSE-AHF trial likewise found that adding low-dose nesiritide to diuretic therapy did not improve decongestion or renal function.
Evidence assessment
High-quality evidence
Strong here means well-established, not favourable. The distinction matters and is retained after audit. Nesiritide has FDA-approved labelling and a very large replicated randomised evidence base culminating in ASCEND-HF (7,141 patients); all four cited papers were verified against PubMed with matching titles, PMIDs, DOIs, journals, years, sample sizes and effect estimates, and the ASCEND-HF registration NCT00475852 was confirmed on ClinicalTrials.gov. The quality and quantity of human trial data are unambiguous. What that evidence shows is that nesiritide reliably lowers pulmonary capillary wedge pressure and produces at best a small, non-significant improvement in dyspnoea, with no effect on rehospitalisation or 30-day mortality. The confident conclusion supported by strong evidence is that it does not help clinically. Guidelines dropped it and it has fallen out of use.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure Preclinical only
Nesiritide reduced pulmonary capillary wedge pressure by 6.0-9.6 mmHg versus a 2.0 mmHg rise with placebo (p<0.001), with improvement in global clinical status in 60-67% versus 14% (p<0.001). Dose-related hypotension, usually asymptomatic, was the main adverse effect.
Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial Preclinical only
Nesiritide reduced pulmonary capillary wedge pressure more than nitroglycerin or placebo at 3 hours and improved self-reported dyspnoea versus placebo at 3 hours, although by 24 hours differences in dyspnoea between treatments were modest. This surrogate-endpoint trial was the basis for FDA approval in 2001.
Effect of nesiritide in patients with acute decompensated heart failure Preclinical only
Definitive negative result. Dyspnoea improvement favoured nesiritide at 6 hours (44.5% versus 42.1%) and 24 hours (68.2% versus 66.1%) but did not meet the prespecified significance threshold; 30-day death or heart failure rehospitalisation was 9.4% versus 10.1% and 30-day mortality 3.6% versus 4.0%, neither significant. No excess of worsening renal function, but significantly more hypotension. The authors concluded nesiritide cannot be recommended for routine use.
Safety
Hypotension is the principal and dose-related adverse effect, symptomatic in a substantial minority and sometimes prolonged because the drug cannot be removed quickly once infused. It was significantly more common than placebo in ASCEND-HF. Headache, nausea, dizziness, bradycardia and ventricular arrhythmias have been reported.
The worsening-renal-function signal from the 2005 meta-analyses was influential at the time but was not reproduced in ASCEND-HF, which was far larger and prospectively designed; the honest summary is that the renal concern was probably overstated while the efficacy concern was well founded. Nesiritide should not be used as the primary treatment for cardiogenic shock or when systolic blood pressure is low, since its mechanism is vasodilation. Because it is structurally identical to endogenous BNP, it interferes with BNP assays used to diagnose and monitor heart failure, a practical laboratory point rather than a toxicity.
The wider lesson is worth stating plainly for anyone reading about peptides more generally: nesiritide did exactly what its mechanism predicted at the level of pressures and hormones, and that turned out not to translate into patients feeling better or living longer. Physiological plausibility, however elegant, is not evidence of clinical benefit.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Not licensed. Nesiritide has never held a UK or EU marketing authorisation and is not available in Great Britain. UK management of acute decompensated heart failure uses loop diuretics and, where vasodilation is indicated, nitrates. |
| United States | FDA-approved in August 2001 for intravenous treatment of patients with acutely decompensated heart failure who have dyspnoea at rest or with minimal activity. Following ASCEND-HF it disappeared from guideline recommendations and from routine practice, and it is no longer in general clinical use. |
| WADA (sport) | Not listed on the WADA Prohibited List. Natriuretic peptides are not named in any prohibited class. |
Questions
Because lowering pulmonary capillary wedge pressure is a surrogate, not an outcome. ASCEND-HF measured what patients actually care about (breathlessness, rehospitalisation, death) in 7,141 people and found no meaningful benefit. Acute heart failure decompensation is driven by congestion, myocardial injury, renal dysfunction and comorbidity together, and a short infusion that transiently improves pressures does not alter that trajectory. It is one of the clearest demonstrations in cardiology that a mechanistically sound intervention can fail on the endpoints that matter.
Yes. Nesiritide is recombinant human BNP-32, structurally identical to the hormone that laboratories measure. That has a practical consequence: an infusion of nesiritide interferes with BNP assays, so BNP concentrations measured during or shortly after treatment cannot be interpreted in the usual way. NT-proBNP, a different fragment, is not affected in the same manner.
Both exploit the natriuretic peptide system but from opposite directions. Nesiritide infuses the hormone directly. Sacubitril inhibits neprilysin, the enzyme that degrades endogenous natriuretic peptides, so concentrations rise physiologically and continuously rather than in a short infusion, and, combined with valsartan, that approach did produce a mortality benefit in chronic heart failure. The contrast suggests the system is a valid target and that the problem with nesiritide was the mode and setting of delivery, not the biology.
No. It has never held a UK or EU marketing authorisation. It was approved only in the United States, in 2001, and after ASCEND-HF it disappeared from guidelines and from routine practice there as well.